FDA clearance de-risks the regulatory path for PALI-2108 in Crohn's disease, but the open-label single-arm design and distant readout (Q1 2028) mean the stock catalyst is procedural, not data-driven. Monitor for enrollment updates and any early safety signals; the next meaningful binary event is the Week 12 endoscopic response data in ~2 years.
Price Chart
Executive Summary
Palisade Bio announced FDA clearance of its IND application for PALI-2108, enabling initiation of the Phase 2 ASCENTRA-CD trial in moderate to severe Crohn's disease. The open-label, single-arm study will enroll ~60 patients with a primary endoscopic response endpoint at Week 12, with first dosing targeted for Q1 2027 and readout in Q1 2028. This expands the PALI-2108 program into a second major IBD indication alongside ulcerative colitis, but the early-stage nature and distant timeline limit near-term impact.
Key Facts
- FDA cleared IND for PALI-2108 to start Phase 2 ASCENTRA-CD trial in moderate to severe Crohn's disease
- Phase 2 trial is open-label, single-arm, enrolling ~60 patients
- Primary endpoint: endoscopic response (≥50% reduction in SES-CD) at Week 12
- First patient dosing targeted for Q1 2027; primary efficacy readout targeted for Q1 2028
- PALI-2108 previously evaluated in fibrostenotic Crohn's disease with encouraging tissue exposure, PDE4 target engagement, and endoscopic activity
- PALI-2108 is a once-daily oral PDE4 inhibitor prodrug activated in terminal ileum and colon
Financial Impact
No financial figures disclosed; clinical-stage biotech with no revenue
Risk Factors
- Open-label, single-arm design limits interpretability of efficacy data
- Distant primary readout (Q1 2028) with no interim catalysts specified
- Early-stage clinical risk: prior results in fibrostenotic Crohn's may not replicate in broader moderate-to-severe population
- Competition from approved PDE4 inhibitors and other IBD therapies
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3366355 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 5w ago | Institutional Cluster | $1.69 $1.43 | ▼ −15.38% | ▼ −14.82% | $1.20 (−28.99%) |
Sep 22, 2026 5w ago | Press Release | $1.69 $1.43 | ▼ −15.38% | ▼ −14.82% | $1.20 (−28.99%) |
Aug 10, 2026 11w ago | 8-K | $2.14 $2.05 | ▼ −4.21% | ▼ −3.15% | $1.20 (−43.93%) |
Jul 10, 2026 15w ago | Insider Cluster | $1.89 $2.10 | ▲ +11.11% | ▲ +7.93% | $1.20 (−36.51%) |
Jul 8, 2026 15w ago | Insider Cluster | $1.97 $2.09 | ▲ +6.09% | ▲ +3.85% | $1.20 (−39.09%) |
Jun 11, 2026 19w ago | 8-K | $1.71 $1.96 | ▲ +14.62% | ▲ +12.84% | $1.20 (−29.82%) |
May 22, 2026 22w ago | EFFECT | $1.95 $1.89 | ▼ −3.08% | ▼ −1.66% | $1.20 (−38.46%) |
May 12, 2026 23w ago | S-3 | $1.87 $1.78 | ▼ −4.81% | ▼ −4.20% | $1.20 (−35.83%) |
Apr 29, 2026 25w ago | DEFA14A | $2.00 $2.12 | ▲ +6.00% | ▲ +0.77% | $1.20 (−40.00%) |
Apr 2, 2026 29w ago | 8-K | $1.89 $2.00 | ▲ +5.82% | ▼ −4.06% | $1.20 (−36.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers